National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Adverse Drug Events (ADE) (6)
- Adverse Events (5)
- Anxiety (2)
- Behavioral Health (31)
- Care Management (1)
- Children/Adolescents (5)
- Clinical Decision Support (CDS) (1)
- Comparative Effectiveness (8)
- Complementary and Alternative Medicine (1)
- (-) Depression (43)
- Diabetes (3)
- Diagnostic Safety and Quality (1)
- Disparities (1)
- Elderly (4)
- Electronic Health Records (EHRs) (1)
- Evidence-Based Practice (3)
- Genetics (3)
- Guidelines (2)
- Healthcare Costs (1)
- Health Information Technology (HIT) (2)
- Hospitalization (1)
- Human Immunodeficiency Virus (HIV) (5)
- Intensive Care Unit (ICU) (1)
- Labor and Delivery (1)
- Long-Term Care (1)
- Medicaid (1)
- Medical Expenditure Panel Survey (MEPS) (1)
- Medicare (2)
- (-) Medication (43)
- Medication: Safety (2)
- Neurological Disorders (1)
- Nursing Homes (1)
- Opioids (2)
- Outcomes (2)
- Pain (1)
- Patient-Centered Outcomes Research (4)
- Patient Adherence/Compliance (9)
- Patient and Family Engagement (1)
- Patient Safety (3)
- Practice Patterns (2)
- Pregnancy (1)
- Racial and Ethnic Minorities (2)
- Research Methodologies (1)
- Respiratory Conditions (2)
- Risk (4)
- Rural Health (1)
- Sex Factors (1)
- Social Determinants of Health (1)
- Social Stigma (2)
- Stress (1)
- Substance Abuse (1)
- Surgery (2)
- Telehealth (1)
- Tobacco Use (1)
- Treatments (3)
- Vulnerable Populations (1)
- Women (3)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
26 to 43 of 43 Research Studies DisplayedJoyce NR, Schuler MS, Hadland SE
Variation in the 12-month treatment trajectories of children and adolescents after a diagnosis of depression.
The purpose of this longitudinal cohort study was to characterize heterogeneity in 12-month trajectories of psychotherapy and antidepressant treatment in youths with depression. The investigators examined variation in baseline health, health care utilization, and health outcomes across classes with similar patterns of psychotherapy and antidepressant use.
AHRQ-funded; HS022998.
Citation: Joyce NR, Schuler MS, Hadland SE .
Variation in the 12-month treatment trajectories of children and adolescents after a diagnosis of depression.
JAMA Pediatr 2018 Jan;172(1):49-56. doi: 10.1001/jamapediatrics.2017.3808..
Keywords: Depression, Children/Adolescents, Behavioral Health, Medication
Carson NJ, Progovac AM, Wang Y
A decline in depression treatment following FDA antidepressant warnings largely explains racial/ethnic disparities in prescription fills.
The Food and Drug Administration's 2004 antidepressant warning was followed by decreases in antidepressant prescribing for youth. Little is known about how antidepressant prescribing patterns varied by race/ethnicity. This study analyzed Medicaid claims data from four U.S. states (2002-2009) for youth ages 5-17. The authors found that antidepressant prescription fills declined most post-warning for White youth, suggesting that risk information may have diffused less rapidly to prescribers or caregivers of minorities.
AHRQ-funded; HS021486.
Citation: Carson NJ, Progovac AM, Wang Y .
A decline in depression treatment following FDA antidepressant warnings largely explains racial/ethnic disparities in prescription fills.
Depress Anxiety 2017 Dec;34(12):1147-56. doi: 10.1002/da.22681..
Keywords: Medication, Children/Adolescents, Depression, Guidelines, Racial and Ethnic Minorities
Cosgrove L, Krimsky S, Wheeler EE
Conflict of interest policies and industry relationships of guideline development group members: A cross-sectional study of clinical practice guidelines for depression.
The purpose of the present study was to assess a) the disclosure requirements of guideline development groups in a cross-section of guidelines for major depression; and, b) the extent and type of conflicts of panel members. It found that most of the guidelines were developed by panels that had members with industry financial ties to drug companies that manufacture antidepressant medication.
AHRQ-funded; HS022940.
Citation: Cosgrove L, Krimsky S, Wheeler EE .
Conflict of interest policies and industry relationships of guideline development group members: A cross-sectional study of clinical practice guidelines for depression.
Account Res 2017;24(2):99-115. doi: 10.1080/08989621.2016.1251319.
.
.
Keywords: Medication, Depression, Guidelines, Behavioral Health, Research Methodologies
Wang S, Mosher C, Gao S
Antidepressant use and depressive symptoms in intensive care unit survivors.
Nearly 30% of intensive care unit (ICU) survivors have depressive symptoms 2-12 months after hospital discharge. In this study, the investigators examined the prevalence of depressive symptoms and risk factors for depressive symptoms in 204 patients at their initial evaluation in the Critical Care Recovery Center (CCRC), an ICU survivor clinic based at Eskenazi Hospital in Indianapolis, Indiana.
AHRQ-funded; HS024384.
Citation: Wang S, Mosher C, Gao S .
Antidepressant use and depressive symptoms in intensive care unit survivors.
J Hosp Med 2017 Sep;12(9):731-34. doi: 10.12788/jhm.2814..
Keywords: Medication, Depression, Intensive Care Unit (ICU), Behavioral Health
Olfson M, Blanco C, Marcus SC
Treatment of adult depression in the United States.
The researchers characterized the treatment of adult depression in the United States. They concluded that most US adults who screen positive for depression did not receive treatment for depression, whereas most who were treated did not screen positive. In light of these findings, it is important to strengthen efforts to align depression care with each patient's clinical needs.
AHRQ-funded; HS02112.
Citation: Olfson M, Blanco C, Marcus SC .
Treatment of adult depression in the United States.
JAMA Intern Med 2016 Oct;176(10):1482-91. doi: 10.1001/jamainternmed.2016.5057.
.
.
Keywords: Medication, Depression, Diagnostic Safety and Quality, Medical Expenditure Panel Survey (MEPS)
Albrecht JS, Park Y, Hur P
Adherence to maintenance medications among older adults with chronic obstructive pulmonary disease. the role of depression.
The objective of this study was to assess the impact of depression on COPD maintenance medication adherence among of Medicare beneficiaries newly diagnosed with COPD. Average monthly adherence to COPD maintenance medications was low, peaking at 57 percent in the month after first fill and decreasing to 35 percent within 6 months. In the adjusted regression model, depression was associated with decreased adherence to COPD maintenance medications.
AHRQ-funded; HS024560.
Citation: Albrecht JS, Park Y, Hur P .
Adherence to maintenance medications among older adults with chronic obstructive pulmonary disease. the role of depression.
Ann Am Thorac Soc 2016 Sep;13(9):1497-504. doi: 10.1513/AnnalsATS.201602-136OC.
.
.
Keywords: Respiratory Conditions, Elderly, Medication, Patient Adherence/Compliance, Depression
O'Connor BC, Lewandowski RE, Rodriguez S
Usual care for adolescent depression from symptom identification through treatment initiation.
The researchers sought to determine rates of appropriate follow-up care for adolescents with newly identified depression symptoms in 3 large health systems. They concluded that most adolescents with newly identified depression symptoms received some treatment, usually including psychotherapy, within the first 3 months after identification. However, follow-up care was low and substantial variation existed between sites.
AHRQ-funded; HS020503.
Citation: O'Connor BC, Lewandowski RE, Rodriguez S .
Usual care for adolescent depression from symptom identification through treatment initiation.
JAMA Pediatr 2016 Apr;170(4):373-80. doi: 10.1001/jamapediatrics.2015.4158.
.
.
Keywords: Medication, Children/Adolescents, Depression, Behavioral Health
Gartlehner G, Gaynes BN, Amick HR
Comparative benefits and harms of antidepressant, psychological, complementary, and exercise treatments for major depression: An evidence report for a clinical practice guideline from the American College of Physicians.
This evidence report compared the benefits and harms of second-generation antidepressants and psychological, complementary and alternative medicine (CAM), and exercise treatments as first- and second-step interventions for adults with acute major depressive disorder (MDD). It concluded tht, given their similar efficacy, cognitive behavioral therapy and antidepressants are both viable choices for initial treatment of MDD.
AHRQ-funded.
Citation: Gartlehner G, Gaynes BN, Amick HR .
Comparative benefits and harms of antidepressant, psychological, complementary, and exercise treatments for major depression: An evidence report for a clinical practice guideline from the American College of Physicians.
Ann Intern Med 2016 Mar 1;164(5):331-41. doi: 10.7326/m15-1813.
.
.
Keywords: Medication, Comparative Effectiveness, Complementary and Alternative Medicine, Depression, Behavioral Health
Amick HR, Gartlehner G, Gaynes BN
Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis.
This systematic review sought to identify the benefits and harms of second generation antidepressants and cognitive behavioral therapies (CBTs) in the initial treatment of a current episode of major depressive disorder in adults. It concluded that the available evidence suggests no difference in treatment effects of second generation antidepressants and CBT, either alone or in combination, although small numbers may preclude detection of small but clinically meaningful differences.
AHRQ-funded; 290-2012-00008I
Citation: Amick HR, Gartlehner G, Gaynes BN .
Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis.
BMJ 2015 Dec 8;351:h6019. doi: 10.1136/bmj.h6019..
Keywords: Medication, Behavioral Health, Comparative Effectiveness, Depression
Sorkin DH, Billimek J, August KJ
AHRQ Author: Ngo-Metzger Q
Mental health symptoms and patient-reported diabetes symptom burden: implications for medication regimen changes.
The aim of this paper was to examine the relative contribution of glycaemic control (HbA1C) and depressive symptoms on diabetes-related symptom burden (hypoglycaemia and hyperglycaemia) in order to guide medication modification. The authors found that mental health symptoms are associated with higher levels of patient-reported diabetes-related symptoms, but the association between diabetes-related symptoms and subsequent regimen modifications is diminished in patients with greater depressive symptoms.
AHRQ-authored.
Citation: Sorkin DH, Billimek J, August KJ .
Mental health symptoms and patient-reported diabetes symptom burden: implications for medication regimen changes.
Fam Pract 2015 Jun;32(3):317-22. doi: 10.1093/fampra/cmv014.
.
.
Keywords: Depression, Diabetes, Medication, Practice Patterns, Social Determinants of Health
Samples H, Mojtabai R
Antidepressant self-discontinuation: results from the collaborative psychiatric epidemiology surveys.
The authors examined the extent and correlates of self-discontinuation of antidepressant medications without physician advice using the Collaborative Psychiatric Epidemiology Surveys. They concluded that physicians prescribing antidepressants need to communicate clearly about the expected benefits of treatment, the minimum duration of use required to experience benefits, and the potential side effects of these medications, particularly to younger patients, those with anxiety disorders, and patients treated in general medical settings, all of whom have increased odds of self-discontinuation.
AHRQ-funded; HS000029.
Citation: Samples H, Mojtabai R .
Antidepressant self-discontinuation: results from the collaborative psychiatric epidemiology surveys.
Psychiatr Serv 2015 May;66(5):455-62. doi: 10.1176/appi.ps.201400021.
.
.
Keywords: Medication, Depression, Medication: Safety, Behavioral Health, Patient Adherence/Compliance
Mayberry LS, Egede LE, Wagner JA
Stress, depression and medication nonadherence in diabetes: test of the exacerbating and buffering effects of family support.
The researchers tested the moderation hypotheses that the associations between stressors/depressive symptoms and nonadherence would be stronger in the context of more obstructive family behaviors (exacerbating hypothesis) and weaker in the context of more supportive family behaviors (buffering hypothesis). They found that stressors and nonadherence were only associated at higher levels of obstructive family behaviors. Similarly, depressive symptoms and nonadherence were only associated at higher levels of obstructive family behaviors.
AHRQ-funded; HS022990.
Citation: Mayberry LS, Egede LE, Wagner JA .
Stress, depression and medication nonadherence in diabetes: test of the exacerbating and buffering effects of family support.
J Behav Med 2015 Apr;38(2):363-71. doi: 10.1007/s10865-014-9611-4..
Keywords: Diabetes, Medication, Patient Adherence/Compliance, Depression, Stress
Adams AS, Soumerai SB, Zhang F
Effects of eliminating drug caps on racial differences in antidepressant use among dual enrollees with diabetes and depression.
This study aimed to evaluate the impact of removing a significant financial barrier to prescription medications (drug caps) on existing black-white disparities in antidepressant treatment rates among patients with diabetes and comorbid depression. It found that policies that remove financial barriers to medications may increase depression treatment rates among patients with diabetes overall while exacerbating treatment disparities.
AHRQ-funded; HS018577; HS018072.
Citation: Adams AS, Soumerai SB, Zhang F .
Effects of eliminating drug caps on racial differences in antidepressant use among dual enrollees with diabetes and depression.
Clin Ther 2015 Mar;37(3):597-609. doi: 10.1016/j.clinthera.2014.12.011..
Keywords: Medication, Disparities, Depression, Diabetes, Healthcare Costs
Gibbons RD, Coca Perraillon M, Hur K
Antidepressant treatment and suicide attempts and self-inflicted injury in children and adolescents.
This study explores the relationship between antidepressant treatment and suicide attempt and self-inflicted injury in depressed children ages 5–17. Using two large claim datasets (LifeLink and MarketScan), the researchers find that after taking into account the time-varying effect of confounders, the apparent link between antidepressant use and suicide attempts and self-inflicted injury is diminished and not statistically significant.
AHRQ-funded; HS021093; HS000084
Citation: Gibbons RD, Coca Perraillon M, Hur K .
Antidepressant treatment and suicide attempts and self-inflicted injury in children and adolescents.
Pharmacoepidemiol Drug Saf 2015 Feb;24(2):208-14. doi: 10.1002/pds.3713..
Keywords: Medication, Children/Adolescents, Depression, Risk
Madden JM, Adams AS, LeCates RF
Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D.
This study examined the effects of transitioning to Part D coverage among disabled dual enrollees with schizophrenia or a bipolar disorder, comparing enrollees in states with strict Medicaid cap policies with enrollees in states without caps. It found significant reductions in the number of people with a serious mental illness who were not treated owing to the transition to Part D from strictly capped Medicaid coverage.
AHRQ-funded; HS018577.
Citation: Madden JM, Adams AS, LeCates RF .
Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D.
JAMA Psychiatry 2015 Feb;72(2):179-88. doi: 10.1001/jamapsychiatry.2014.1259..
Keywords: Behavioral Health, Medication, Medicare, Medicaid, Depression
Olfson M, Gerhard T
Re-examining antidepressant risk of self-injury in children and adolescents.
This commentary discusses issues raised in the study by Gibbons, et al. that focused on the association between antidepressant treatment and risk of medically injurious self-inflicted harm in young people diagnosed with depression. One example is the threat of unmeasured confounding that arises from the wide range of self-injury risk factors that are not represented in claims data.
AHRQ-funded; HS021112.
Citation: Olfson M, Gerhard T .
Re-examining antidepressant risk of self-injury in children and adolescents.
Pharmacoepidemiol Drug Saf 2015 Feb;24(2):215-7. doi: 10.1002/pds.3737..
Keywords: Medication, Children/Adolescents, Depression, Risk
Bobo WV, Reilly-Harrington NA, Ketter TA
Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial.
This study investigated the longer-term effects of adjunctive benzodiazepines on symptom response during treatment in patients with bipolar disorders. The investigators concluded that adjunctive benzodiazepines may not significantly affect clinical outcome in lithium- or quetiapine-treated patients with bipolar I or II disorder over 6 months, after controlling for potential confounding factors.
AHRQ-funded; HS019371.
Citation: Bobo WV, Reilly-Harrington NA, Ketter TA .
Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial.
J Affect Disord 2014 Jun;161:30-5. doi: 10.1016/j.jad.2014.02.046..
Keywords: Comparative Effectiveness, Depression, Medication, Behavioral Health, Treatments
Bao Y, Ryan AM, Shao H
Generic initiation and antidepressant therapy adherence under Medicare Part D.
This study assessed the effects of initiating antidepressant treatment with a generic versus a branded prescription (generic initiation) on adherence to antidepressant therapy for the treatment of depression. It found that starting patients with generics had benefits for antidepressant adherence by lowering out-of-pocket costs for all patients and by mitigating the effect of the Part D coverage gap faced by patients not receiving low-income subsidies.
AHRQ-funded; HS018546.
Citation: Bao Y, Ryan AM, Shao H .
Generic initiation and antidepressant therapy adherence under Medicare Part D.
Am J Manag Care 2013 Dec;19(12):989-98..
Keywords: Medication, Depression, Medicare, Patient Adherence/Compliance